Danazol in hemophilia
Other
OA: closed
CC0
AI-generated summary
A two-week trial of high-dose danazol combined with aminocaproic acid in 20 adults with hemophilia showed increased factor levels in only two patients, failing to demonstrate broad therapeutic efficacy.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
To the Editor.— In a recent article Garewal et al1demonstrated that danazol, an attenuated androgen, given at a dose of 600 mg daily for eight to 14 weeks, is not useful in the treatment of factor VIII—deficient and factor IX—deficient hemophilic patients. Some hemophilic patients experienced abnormal bleeding with danazol—a problem attributed to increased fibrinolysis.1,2 Subjects and Methods.— In 1984, we undertook a two-week trial of danazol in 800-mg/day oral doses, in addition to aminocaproic acid in 10-g/day oral doses as an inhibitor of fibrinolysis. The subjects were 20 adults with hemophilia and no factor VIII inhibitor, nor evidence of active bleeding. Eighteen cases had moderate to mild hemophilia A (3.2% to 10% of factor VIII), and two cases had moderate hemophilia B (3% and 4.2% of factor IX). Two of the 20 patients showed an increase in deficient factor levels: one with an initial factor VIII
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
References (5)
- Danazol in hemophilia via openalex
- Effect of danazol on coagulation parameters and bleeding in hemophilia via openalex
- Poor response to danazol in hemophilia via openalex
- doi:10.1056/nejm198408303110914 via openalex
- doi:10.1016/0049-3848(84)90165-8 via openalex
Source provenance
- crossref
- last seen: 2026-08-26T06:23:00.087416+00:00
- openalex
- last seen: 2026-05-11T04:44:38.335450+00:00
- pubmed
- last seen: 2026-10-08T21:48:32.119780+00:00
- unpaywall
- last seen: 2026-10-09T06:36:44.367587+00:00
License: CC0
· commercial use OK